Pfizer plans to test a combination of three novel cancer drugs in humans next year, reports David Crow of The Financial Times. With the coming trial, the U.S.-based drugmaker seeks to make up lost ground in the race to develop a new generation of “immunotherapy" medicines.
The three-drug combination will be known as a “TRIPLET” trial and be the first one of its kind in the immuno-oncology segment.
According to Business Finance News, in the beginning, the clinical study is expected to be on a short scale just to ascertain the safety and efficacy profile of the combination drugs.
Reports indicate that, depending on the potential successful trial of the combination therapy, the main factor to consider will be the drug’s cost.